Drug
PF-06372865 clinical trials
Also written PF-06372865, CVL-865 and Darigabat.
- studies test it
- 15
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How studies write it
Studies that test it under each name
Development codes
Other names
Studies by the year they started
15 studies that test it; most in 2014 (5)
| Year | Studies |
|---|---|
| 2014 | 5 |
| 2015 | 2 |
| 2017 | 1 |
| 2020 | 3 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses PF-06372865 is read from its arms, and is right about nine times in ten.
Testing it · 15
- A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic DisorderTerminatedPhase 2AbbVieNCT05941442Written as Darigabat
- An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset SeizuresTerminatedPhase 2AbbVieNCT04686786Written as CVL-865
- A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset SeizuresCompletedPhase 2AbbVieNCT04244175Written as CVL-865
- A Trial to Assess the Absorption, Metabolism, Excretion, and Mass Balance of [14C]-Darigabat After a Single Oral Dose in Healthy Male ParticipantsCompletedPhase 1Cerevel Therapeutics, LLCNCT06435923Written as [14C]-darigabat
- Open-label Trial to Evaluate the Effect Carbamazepine on Darigabat Pharmacokinetics in Healthy Adult ParticipantsCompletedPhase 1Cerevel Therapeutics, LLCNCT05824143Written as Darigabat
- Relative Bioavailability and Food Effect Following Single Oral Dose of Darigabat Tablet Formulations in Healthy ParticipantsCompletedPhase 1Cerevel Therapeutics, LLCNCT05123079Written as Darigabat
- A Trial of the Effect of CVL-865 on Panic Symptoms Induced by Carbon Dioxide Inhalation in Healthy SubjectsCompletedPhase 1Cerevel Therapeutics, LLCNCT04592536Written as CVL-865 High dose
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Repeat Doses of PF-06372865 in Healthy SubjectsCompletedPhase 1PfizerNCT03351751Written as PF-06372865
- PF-06372865 in Subjects With Photosensitive EpilepsyCompletedPhase 2PfizerNCT02564029Written as PF-06372865
- An Open-label, Two-period, Fixed-sequence Study to Evaluate Multiple-dose Itraconazole Effect on The Single-dose PK of PF-06372865 in Healthy SubjectsWithdrawnPhase 1PfizerNCT02475746Written as PF-06372865
- PF-06372865 In Subjects With Chronic Low Back PainCompletedPhase 2PfizerNCT02262754Written as PF-06372865
- Assessment of the Analgesic Effects of PF-06372865 in Healthy Volunteers Using Evoked Pain EndpointsCompletedPhase 1PfizerNCT02238717Written as PF-06372865 (65mg)
- Food Effect Study for PF-06372865CompletedPhase 1PfizerNCT02217787Written as PF-06372865
- A Study to Examine the Distribution of PF-06372865 in the Brain of Healthy Volunteers Using Positron Emission Tomography and a Radioactive Tracer Following Oral Administration of One Dose of PF-06372865CompletedPhase 1PfizerNCT02138500Written as PF-06372865
- A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06372865 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)CompletedPhase 1PfizerNCT02070289Written as PF-06372865
Codes
What other systems call PF-06372865 · ClinicalTrials.gg INT001063
- MeSH (NLM) C000630159PF-06372865One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000630159 | PF-06372865 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.